Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;4(Suppl 3):1-6.
Epub 2020 Dec 30.

First Analysis of Same-day Pegfilgrastim Use with Concurrent Capecitabine-based Regimens in Patients with Gastrointestinal Malignancies

Muhammad Wasif Saif  1 , Nausheen Hakim  1 , Jeffrey Chi  1 , Hasan Rehman  1 , Shreya Prasad Goyal  1 , Coral Olazagasti  1 , Patnita Forde Sheperd  1 , Jyothi Jose  1
Affiliations

First Analysis of Same-day Pegfilgrastim Use with Concurrent Capecitabine-based Regimens in Patients with Gastrointestinal Malignancies

Muhammad Wasif Saif et al. Cancer Med J. 2021 Mar.

Abstract

Background: Pegfilgrastim is administered 24 hours. after chemotherapy to reduce risks of myelosuppression. This requires an additional clinic visit, which can be difficult for some patients (pts) due to work and transportation issues. In GI malignancies, patients receiving capecitabine-based regimens also require pegfilgrastim to reduce myelotoxicity. We present here the first study to analyze safety and efficacy of administering pegfilgrastim on the same day as capecitabine-based regimens in patients with GI malignancies.

Methods: We evaluated 157 patients with GI malignancies who received a capecitabine-based chemotherapy regimen, including XELOX, EOX, ECX, XELIRI, MIXE, gemcitabine-capecitabine and same-day pegfilgrastim (6 mg) within 1 hr of completion of systemic agents. As per institutional guidelines, patients were counseled on risks of same-day pegfilgrastim prior to its administration. Patients were followed to determine the degree of neutropenia and toxicity.

Results: A total of 914 chemotherapy cycles in 157 patients were analyzed. Median ANC nadir for all cycles was 5634/uL (range: 450 - 23800). Grade 1 and 2 neutropenia developed in 11 of 914 cycles. Bone pain reported in 9 pts. There was 1 episode of grade >3 neutropenia resulting in infection and antibiotic use. No other patient required dose reductions, chemotherapy delays, or hospitalizations. No increased toxicity of capecitabine was noticed.

Conclusions: We believe our study is the first in GI malignancies to report that same-day pegfilgrastim administration with capecitabine-based regimens may be as effective and safe as next-day administration. Additionally, given the absence of CD in human bone marrow, it appears capecitabine can be used concurrently with pegfilgrastim. Prospective studies should be done to further investigate, as this practice can benefit patients clinically, decrease office visits, increase patient's satisfaction and reduce healthcare costs.

Keywords: Capecitabine; Chemotherapy; Fever; Leukopenia; Neutropenia; Pegfilgrastim; Side effects.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Metabolic pathway of capecitabine [15].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kuderer NM, Dale DC, Crawford J, et al. (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10): 2258–2266. - PubMed
    1. Bhana N (2007) Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: Evidence based review. Current Opinion in Oncology 19(4): 328–335. - PubMed
    1. Meropol NJ, Miller LL, Korn EL, et al. (1992) Severed myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. JNCI: Journal of the National Cancer Institute 84(15): 1201–1203. - PubMed
    1. Saif MW, Kaley K, Brennan M, et al. (2013) A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. Journal of the Pancreas 14(5): 498–501. - PubMed
    1. Saif MW, Kaley K, Brennan M, et al. (2013) Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: A retrospective study. Anticancer Research 33(6): 2743–2746. - PubMed

LinkOut - more resources